{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,11]],"date-time":"2026-06-11T15:02:41Z","timestamp":1781190161693,"version":"3.54.1"},"reference-count":30,"publisher":"Oxford University Press (OUP)","issue":"6","license":[{"start":{"date-parts":[[2026,5,6]],"date-time":"2026-05-06T00:00:00Z","timestamp":1778025600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100003042","name":"Else Kr\u00f6ner-Fresenius-Stiftung","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100003042","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100007952","name":"Eva Luise und Horst K\u00f6hler Stiftung","doi-asserted-by":"publisher","award":["2019_KollegSE.04"],"award-info":[{"award-number":["2019_KollegSE.04"]}],"id":[{"id":"10.13039\/501100007952","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2026,6,1]]},"abstract":"<jats:title>ABSTRACT<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Up to 8% of renal tumors have a monogenic cause, yet hereditary renal cell carcinoma (hRCC) syndromes such as von Hippel\u2013Lindau (VHL), Tuberous Sclerosis Complex (TSC), Birt\u2013Hogg\u2013Dub\u00e9 (BHD), and Hereditary Leiomyomatosis and Renal Cell Cancer remain underdiagnosed. Early diagnosis is critical for patient management, genetic counseling, and family screening. We developed and prospectively validated a structured risk assessment tool (hRCC score) for identifying patients at risk of hereditary renal tumors.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>A prospective single-center study was conducted at the University Hospital Cologne (2020\u20132022) including 200 patients with histologically confirmed renal tumors. The hRCC score incorporated age at diagnosis, multifocal\/bilateral disease, histology, extrarenal manifestations, and family history. Patients with a score \u22651.5 were referred for genetic testing using a multiplex MLPA (Multiplex Ligand-dependent Probe Amplification)-based panel including TSC, MET, VHL, FH, SDH-A-D, and FLCN.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Of 195 eligible patients, 34.4% (n\u00a0=\u00a067) had a high-risk hRCC score (\u22651.5). Overall, 71 (36.4%) underwent genetic testing; a pathogenic or likely pathogenic variant was detected in 50.7% of tested patients, corresponding to 18.5% of the total cohort. The most common diagnoses were TSC (58.3%), VHL (16.7%), and BHD (11.1%). Confirmed hereditary cases had significantly higher mean hRCC scores (4.67\u00a0vs 0.48, P\u00a0&amp;lt;\u00a0.0001). Extrarenal manifestations and bilateral or multifocal disease were the strongest predictors. The cutoff of 1.5 yielded 97.2% sensitivity and 79.8% specificity.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>The hRCC score is an effective clinical screening tool for detecting patients at risk for hereditary renal tumors, demonstrating high diagnostic yield and supporting targeted referral for genetic evaluation.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1093\/ckj\/sfag143","type":"journal-article","created":{"date-parts":[[2026,5,6]],"date-time":"2026-05-06T11:30:32Z","timestamp":1778067032000},"source":"Crossref","is-referenced-by-count":0,"title":["Hereditary kidney tumor syndromes: structured evaluation of a questionnaire-based approach"],"prefix":"10.1093","volume":"19","author":[{"ORCID":"https:\/\/orcid.org\/0009-0005-1107-7104","authenticated-orcid":false,"given":"Jan","family":"Degenhardt","sequence":"first","affiliation":[{"name":"Department II of Internal Medicine, University of Cologne, Faculty of Medicine and University Hospital Cologne , Cologne ,","place":["Germany"]},{"name":"Research Center On Rare Kidney Disease (RECORD), University Hospital Erlangen , Erlangen ,","place":["Germany"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Theresa","family":"von\u00a0Zehmen","sequence":"additional","affiliation":[{"name":"Department of Urology, Uro-Oncology, Robot-Assisted and Reconstructive Urologic Surgery, University of Cologne, Faculty of Medicine and University Hospital Cologne , Cologne ,","place":["Germany"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bodo","family":"Beck","sequence":"additional","affiliation":[{"name":"Institute of Human Genetics, University Hospital Cologne and University of Cologne, Faculty of Medicine , Cologne ,","place":["Germany"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Florian","family":"Erger","sequence":"additional","affiliation":[{"name":"Institute of Human Genetics, University Hospital Cologne and University of Cologne, Faculty of Medicine , Cologne ,","place":["Germany"]},{"name":"University Medicine Greifswald, Institute for Molecular Genomics, Core Unit Genomics , Greifswald ,","place":["Germany"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Axel","family":"Heidenreich","sequence":"additional","affiliation":[{"name":"Department of Urology, Uro-Oncology, Robot-Assisted and Reconstructive Urologic Surgery, University of Cologne, Faculty of Medicine and University Hospital Cologne , Cologne ,","place":["Germany"]},{"name":"Department of Urology, Medical University Vienna ,","place":["Austria"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6910-0745","authenticated-orcid":false,"given":"Roman-Ulrich","family":"M\u00fcller","sequence":"additional","affiliation":[{"name":"Department II of Internal Medicine, University of Cologne, Faculty of Medicine and University Hospital Cologne , Cologne ,","place":["Germany"]},{"name":"Cluster of Excellence on Cellular Stress Responses in Aging-associated Diseases (CECAD), University of Cologne , Cologne ,","place":["Germany"]},{"name":"Department of Nephrology, Medical Faculty, University Hospital D\u00fcsseldorf, Heinrich-Heine-University D\u00fcsseldorf , D\u00fcsseldorf ,","place":["Germany"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pia","family":"Paffenholz","sequence":"additional","affiliation":[{"name":"Department of Urology, Uro-Oncology, Robot-Assisted and Reconstructive Urologic Surgery, University of Cologne, Faculty of Medicine and University Hospital Cologne , Cologne ,","place":["Germany"]},{"name":"Center for Integrated Oncology (CIO) K\u00f6ln-Bonn , Cologne ,","place":["Germany"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2026,5,6]]},"reference":[{"key":"2026061110280787200_bib1","doi-asserted-by":"publisher","first-page":"476","DOI":"10.1016\/S0140-6736(24)00917-6","article-title":"Renal cell carcinoma","volume":"404","author":"Young","year":"2024","journal-title":"The Lancet"},{"key":"2026061110280787200_bib2","doi-asserted-by":"publisher","first-page":"1001","DOI":"10.1001\/jama.2024.12848","article-title":"Renal cell carcinoma: a review","volume":"332","author":"Rose","year":"2024","journal-title":"JAMA"},{"key":"2026061110280787200_bib3","doi-asserted-by":"publisher","first-page":"458","DOI":"10.1016\/j.eururo.2022.06.016","article-title":"The 2022 World Health Organization classification of tumours of the urinary system and male genital organs\u2013Part A: renal, penile, and testicular tumours","volume":"82","author":"Moch","year":"2022","journal-title":"Eur Urol"},{"key":"2026061110280787200_bib4","doi-asserted-by":"publisher","first-page":"529","DOI":"10.1016\/j.eururo.2022.08.019","article-title":"Epidemiology of renal cell carcinoma: 2022 update","volume":"82","author":"Bukavina","year":"2022","journal-title":"Eur Urol"},{"key":"2026061110280787200_bib5","doi-asserted-by":"publisher","first-page":"E214","DOI":"10.5489\/cuaj.3798","article-title":"Structured assessment and followup for patients with hereditary kidney tumour syndromes [published correction appears in Can Urol Assoc J. 2017 Aug;11(8):E325. doi: 10.5489\/cuaj.4832]","volume":"10","author":"Lattouf","year":"2016","journal-title":"Can Urol Assoc J"},{"key":"2026061110280787200_bib6","doi-asserted-by":"publisher","first-page":"431","DOI":"10.1200\/JCO.2013.50.8192","article-title":"Defining early-onset kidney cancer: implications for germline and somatic mutation testing and clinical management","volume":"32","author":"Shuch","year":"2014","journal-title":"J Clin Oncol"},{"key":"2026061110280787200_bib7","doi-asserted-by":"publisher","first-page":"334","DOI":"10.1097\/MOU.0000000000000646","article-title":"Inherited kidney cancer syndromes","volume":"29","author":"Ball","year":"2019","journal-title":"Curr Opin Urol"},{"key":"2026061110280787200_bib8","doi-asserted-by":"publisher","first-page":"133","DOI":"10.1016\/j.ucl.2012.01.006","article-title":"The surgical approach to multifocal renal cancers: hereditary syndromes, ipsilateral multifocality, and bilateral tumors","volume":"39","author":"Shuch","year":"2012","journal-title":"Urol Clin North Am"},{"key":"2026061110280787200_bib9","doi-asserted-by":"publisher","first-page":"2036","DOI":"10.1056\/NEJMoa2103425","article-title":"Belzutifan for renal cell carcinoma in von Hippel-Lindau disease","volume":"385","author":"Jonasch","year":"2021","journal-title":"N Engl J Med"},{"key":"2026061110280787200_bib10","doi-asserted-by":"publisher","first-page":"5004","DOI":"10.1200\/JCO.2020.38.15_suppl.5004","article-title":"Results from a phase II study of bevacizumab and erlotinib in subjects with advanced hereditary leiomyomatosis and renal cell cancer (HLRCC) or sporadic papillary renal cell cancer","volume":"38","author":"Srinivasan","year":"2020","journal-title":"J Clin Oncol"},{"key":"2026061110280787200_bib11","doi-asserted-by":"publisher","first-page":"71","DOI":"10.1097\/JU.0000000000003765","article-title":"Family history and risk of renal cell carcinoma: a national multiregister case-control study","volume":"211","author":"Jakobsson","year":"2024","journal-title":"J Urol"},{"key":"2026061110280787200_bib12","doi-asserted-by":"publisher","first-page":"184","DOI":"10.1053\/j.semdp.2018.01.005","article-title":"Morphological clues to the appropriate recognition of hereditary renal neoplasms","volume":"35","author":"Moch","year":"2018","journal-title":"Semin Diagn Pathol"},{"key":"2026061110280787200_bib13","doi-asserted-by":"publisher","first-page":"3957","DOI":"10.1002\/cncr.33679","article-title":"Genetic risk assessment for hereditary renal cell carcinoma: clinical consensus statement","volume":"127","author":"Bratslavsky","year":"2021","journal-title":"Cancer"},{"key":"2026061110280787200_bib14","doi-asserted-by":"publisher","first-page":"e10","DOI":"10.1016\/j.clon.2019.07.010","article-title":"Application of hereditary renal cell carcinoma risk criteria to a large prospective database","volume":"32","author":"Kushnir","year":"2020","journal-title":"Clin Oncol"},{"key":"2026061110280787200_bib15","doi-asserted-by":"publisher","first-page":"355","DOI":"10.1016\/j.cell.2018.03.039","article-title":"Pathogenic germline variants in 10,389 adult cancers","volume":"173","author":"Huang","year":"2018","journal-title":"Cell"},{"key":"2026061110280787200_bib16","doi-asserted-by":"publisher","first-page":"1228","DOI":"10.1001\/jamaoncol.2018.1986","article-title":"Prevalence of germline mutations in cancer susceptibility genes in patients with advanced renal cell carcinoma","volume":"4","author":"Carlo","year":"2018","journal-title":"JAMA Oncol"},{"key":"2026061110280787200_bib17","doi-asserted-by":"publisher","first-page":"104538","DOI":"10.1016\/j.ejmg.2022.104538","article-title":"von Hippel-Lindau disease: updated guideline for diagnosis and surveillance","volume":"65","author":"Louise","year":"2022","journal-title":"Eur J Med Genet"},{"key":"2026061110280787200_bib18","doi-asserted-by":"publisher","first-page":"2927","DOI":"10.1002\/cncr.34896","article-title":"Guidelines for surveillance of patients with von Hippel-Lindau disease: consensus statement of the International VHL Surveillance Guidelines Consortium and VHL Alliance","volume":"129","author":"Daniels","year":"2023","journal-title":"Cancer"},{"key":"2026061110280787200_bib19","doi-asserted-by":"publisher","first-page":"1542","DOI":"10.1038\/s41431-024-01671-2","article-title":"ERN GENTURIS clinical practice guidelines for the diagnosis, surveillance and management of people with Birt-Hogg-Dub\u00e9 syndrome","volume":"32","author":"Geilswijk","year":"2024","journal-title":"Eur J Hum Genet"},{"key":"2026061110280787200_bib20","doi-asserted-by":"publisher","first-page":"50","DOI":"10.1016\/j.pediatrneurol.2021.07.011","article-title":"Updated international tuberous sclerosis complex diagnostic criteria and surveillance and management recommendations","volume":"123","author":"Northrup","year":"2021","journal-title":"Pediatr Neurol"},{"key":"2026061110280787200_bib21","doi-asserted-by":"publisher","first-page":"402","DOI":"10.1038\/s41581-024-00818-0","article-title":"Clinical practice recommendations for kidney involvement in tuberous sclerosis complex: a consensus statement by the ERKNet Working Group for Autosomal Dominant Structural Kidney Disorders and the ERA Genes & Kidney Working Group","volume":"20","author":"Mekahli","year":"2024","journal-title":"Nat Rev Nephrol"},{"key":"2026061110280787200_bib22","doi-asserted-by":"publisher","first-page":"e2132615","DOI":"10.1001\/jamanetworkopen.2021.32615","article-title":"Assessment of risk of hereditary predisposition in patients with melanoma and\/or mesothelioma and renal neoplasia","volume":"4","author":"Gupta","year":"2021","journal-title":"JAMA Netw Open"},{"key":"2026061110280787200_bib23","doi-asserted-by":"publisher","first-page":"1328","DOI":"10.1093\/jnci\/djy171","article-title":"Comprehensive study of the clinical phenotype of germline BAP1 variant-carrying families worldwide","volume":"110","author":"Walpole","year":"2018","journal-title":"J Natl Cancer Inst"},{"key":"2026061110280787200_bib24","doi-asserted-by":"publisher","first-page":"1022","DOI":"10.1038\/ng.912","article-title":"Germline BAP1 mutations predispose to malignant mesothelioma","volume":"43","author":"Testa","year":"2011","journal-title":"Nat Genet"},{"key":"2026061110280787200_bib25","doi-asserted-by":"publisher","first-page":"3001","DOI":"10.1093\/hmg\/ddac089","article-title":"Frequency of pathogenic germline variants in cancer susceptibility genes in 1336 renal cell carcinoma cases","volume":"31","author":"Yngvadottir","year":"2022","journal-title":"Hum Mol Genet"},{"key":"2026061110280787200_bib26","doi-asserted-by":"publisher","first-page":"30","DOI":"10.1016\/j.ejca.2020.12.023","article-title":"Clinical practice guidelines for BRCA1 and BRCA2 genetic testing","volume":"146","author":"Pujol","year":"2021","journal-title":"Eur J Cancer"},{"key":"2026061110280787200_bib27","doi-asserted-by":"publisher","first-page":"611","DOI":"10.1200\/JCO.2015.64.3809","article-title":"American Cancer Society\/American Society of Clinical Oncology Breast Cancer Survivorship Care Guideline","volume":"34","author":"Runowicz","year":"2016","journal-title":"J Clin Oncol"},{"key":"2026061110280787200_bib28","doi-asserted-by":"publisher","first-page":"380","DOI":"10.6004\/jnccn.2020.0017","article-title":"NCCN guidelines insights: genetic\/familial high-risk assessment: breast, ovarian, and pancreatic, version 1.2020","volume":"18","author":"Daly","year":"2020","journal-title":"J Natl Comp Canc Netw"},{"key":"2026061110280787200_bib29","doi-asserted-by":"publisher","first-page":"1407","DOI":"10.1016\/j.gim.2022.04.006","article-title":"ACMG SF v3.1 list for reporting of secondary findings in clinical exome and genome sequencing: a policy statement of the American College of Medical Genetics and Genomics (ACMG)","volume":"24","author":"Miller","year":"2022","journal-title":"Genet Med"},{"key":"2026061110280787200_bib30","article-title":"National Guidelines on Diagnosis, Therapy, and Follow-up of Renal Cell Carcinoma: leitlinienprogramm Onkologie (Deutsche Krebsgesellschaft, Deutsche Krebshilfe, AWMF): diagnostik, Therapie und Nachsorge des Nierenzellkarzinoms, Langversion 3.0, 2021, AWMF-Registernummer: 043\/017OL"}],"container-title":["Clinical Kidney Journal"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/ckj\/advance-article-pdf\/doi\/10.1093\/ckj\/sfag143\/68226233\/sfag143.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/ckj\/article-pdf\/19\/6\/sfag143\/68226233\/sfag143.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/ckj\/article-pdf\/19\/6\/sfag143\/68226233\/sfag143.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,11]],"date-time":"2026-06-11T14:28:14Z","timestamp":1781188094000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/ckj\/article\/doi\/10.1093\/ckj\/sfag143\/8670342"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,5,6]]},"references-count":30,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2026,6,1]]}},"URL":"https:\/\/doi.org\/10.1093\/ckj\/sfag143","relation":{},"ISSN":["2048-8505","2048-8513"],"issn-type":[{"value":"2048-8505","type":"print"},{"value":"2048-8513","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2026,6]]},"published":{"date-parts":[[2026,5,6]]},"article-number":"sfag143"}}